Gyre Therapeutics, Inc.
GYRE
$7.01
-$0.64-8.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.70% | 14.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.70% | 14.17% | |||
| Cost of Revenue | 7.06% | 41.44% | |||
| Gross Profit | 22.52% | 12.94% | |||
| SG&A Expenses | 55.33% | -1.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.84% | -3.91% | |||
| Operating Income | -98.27% | 218.88% | |||
| Income Before Tax | -100.87% | 240.88% | |||
| Income Tax Expenses | -23.21% | 155.74% | |||
| Earnings from Continuing Operations | -123.01% | 276.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 84.65% | -105.11% | |||
| Net Income | -147.73% | 716.74% | |||
| EBIT | -98.27% | 218.88% | |||
| EBITDA | -89.24% | 169.29% | |||
| EPS Basic | -147.61% | 694.00% | |||
| Normalized Basic EPS | -136.43% | 796.67% | |||
| EPS Diluted | -162.46% | 1,486.36% | |||
| Normalized Diluted EPS | -141.70% | 803.85% | |||
| Average Basic Shares Outstanding | 0.34% | 1.94% | |||
| Average Diluted Shares Outstanding | -12.33% | 1.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||